RxDoctor Payments Data

Lauren Okeefe, APRN

Nurse Practitioner · Stamford, CTNPI 1265574560

Payments from drug & device makers

$3,064in general payments, 2019–2025

Across 59 payments — averaging $51.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$640
  • AbbVie$469
  • E.r. Squibb & Sons, L.L.C.$404
  • Pharmacyclics LLC, An Abbvie Company$371
  • Johnson & Johnson$296
  • Daiichi Sankyo Inc.$228
  • plus $656 from 7 others

What the payments were for

  • Food & beverage$2,58884%
  • Education$47616%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,064 in reported general payments places this provider in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$46,398
Medicare patients
270
Services billed
637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide55$987,138
PomalystPomalidomide48$986,936
Lenalidomide32$382,042
EliquisApixaban67$51,200
XareltoRivaroxaban43$39,102
Exemestane46$10,409
Anastrozole161$2,964
Dexamethasone52$1,338
Ondansetron Hcl17$1,111
Warfarin Sodium80$799
Letrozole25$501
Prochlorperazine Maleate32$470
Oxycodone Hcl31$467
Prednisone68$409
Tamoxifen Citrate13$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$207$987,13855 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$404$986,93648 claims
Johnson & JohnsonXarelto$296$39,10243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →